CDx Diagnostics to Present WATS3D Progression Data at DDW 2025
Highlights Continued Progress in Early Detection and the Progression of Esophageal Disease
SUFFERN, N.Y., May 2, 2025 /PRNewswire/ -- CDx Diagnostics announced today that new clinical data supporting the utility of the WATS3D test for Barrett's esophagus and dysplasia screening and surveillance has been selected for podium presentation at the 2025 Digestive Disease Week (DDW) in San Diego, the premier conference for gastroenterology professionals. This podium presentation, along with additional data featured in a separate poster presentation, highlights WATS3D's vital role in early detection, progression monitoring and risk assessment of patients at risk for Barrett's esophagus and esophageal cancer.
WATS3D has consistently shown superior detection rates compared to conventional forceps biopsy (FB), the latter of which can miss up to 50% of cases. By sampling a broader area of mucosa and analyzing more cellular material using advanced 3D imaging, WATS3D may help gastroenterologists detect Barrett's esophagus that might otherwise go undiagnosed.
Key Events at DDW 2025:
Nicholas J. Shaheen, MD will deliver the podium presentation, based on a collaborative study with Dr. Michael Smith, Dr. Vivek Kaul, Mendel Singer Ph.D., and Dr. Robert Odze.
'The findings validate WATS3D's role in early detection,' said Dr. Shaheen. 'We're excited to share these results at DDW and discuss their impact on patient care.'
Robert D. Odze, MD noted that 'These studies advance our understanding of the biological significance of WATS3D detected lesions and their risk of progression to cancer in Barrett's esophagus.'
The new data shared at DDW 2025 from May 3-6 offers important clinical insights into the evolving role of WATS3D in Barrett's detection, surveillance and risk assessment. For more information, visit www.cdxdiagnostics.com or contact us at [email protected].
About CDx Diagnostics
CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. The company's proprietary diagnostic platform combines advanced computer imaging, artificial intelligence, molecular biology, and 3D cytopathology to detect precancerous changes earlier and more precisely than conventional methods. This pioneering solution has analyzed over 400,000 cases, empowering providers to identify those requiring early intervention, reduce time to treatment, and improve outcomes by detecting disease that might be missed by traditional forceps biopsies.
CONTACT:
Logan Garrett
[email protected]
423-519-9979
View original content: https://www.prnewswire.com/news-releases/cdx-diagnostics-to-present-wats3d-progression-data-at-ddw-2025-302444429.html
SOURCE CDx Diagnostics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
European Direct-to-Consumer Genetic Testing Market to Reach USD 3.78 Billion by 2035, Says Meticulous Research®
Market Growth Driven by Increasing Consumer Awareness About Personalized Medicine, Growing Interest in Ancestry Research, Rising Prevalence of Chronic Diseases, and Technological Advancements in Genomic Sequencing REDDING, Calif., June 17, 2025 /PRNewswire/ -- The European direct-to-consumer genetic testing market is expected to reach USD 3.78 billion by 2035, growing from an estimated USD 464 million in 2025, at a CAGR of 23.3% during the forecast period of 2025-2035, according to a new market research report titled "Europe Direct-to-Consumer (DTC) Genetic Testing Market by Test Type (Health, Ancestry, Nutrigenomics, Pharmacogenetics), Technology, Sample Type, Distribution Channel & Region – Forecast to 2035", published by Meticulous Research®. The European DTC genetic testing market is primarily driven by increasing consumer awareness about personalized medicine, growing interest in ancestry and genealogy research, rising prevalence of chronic diseases, and technological advancements in genomic sequencing. The shift towards comprehensive health and wellness testing panels and focus on user-friendly sample collection methods are reshaping the industry, while enhanced data privacy compliance and regulatory frameworks are gaining significant traction. The integration with digital health platforms and telemedicine services and the development of AI-powered genetic interpretation tools are further driving market growth, especially in developed European markets with advanced healthcare infrastructure. Additionally, the growing focus on preventive healthcare and wellness optimization, along with increasing adoption of multi-omics approaches combining genomics with other biological data, are creating new revenue streams for solution providers. Key Market Drivers and Trends The European DTC genetic testing market is experiencing significant transformation through technological advancements in genomic sequencing, AI-powered genetic interpretation tools, and integration with digital health platforms. Leading genetic testing companies are investing heavily in comprehensive testing panels, user-friendly sample collection methods, and enhanced data privacy compliance to improve user experience and expand market reach. These advances are enabling consumers to access personalized health insights while maintaining regulatory compliance across diverse European markets. Recent developments in next-generation sequencing technologies and pharmacogenetic testing capabilities have significantly improved analytical accuracy and clinical utility. The integration of telemedicine services and genetic counseling platforms has transformed DTC genetic testing from simple ancestry analysis into comprehensive health management tools. Read more about the European Direct-to-Consumer Genetic Testing Market- Market Segmentation Insights Health & Disease Predisposition Testing Segment Projected to Hold the Largest Market Share The Health & Disease Predisposition Testing segment is expected to hold the largest share of the overall European DTC genetic testing market in 2025, due to increasing consumer interest in understanding genetic risks for common diseases and growing awareness of preventive healthcare. This segment benefits from rising chronic disease prevalence and consumer demand for proactive health management strategies. However, the Nutrigenomics & Metabolism Testing segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing focus on personalized nutrition, wellness optimization trends, and growing understanding of gene-diet interactions. Next-Generation Sequencing (NGS) Experiencing Highest Growth by Technology The DNA Microarrays segment is expected to dominate the overall European DTC genetic testing market in 2025, primarily due to its cost-effectiveness and suitability for common genetic variant analysis. However, the Next-generation Sequencing (NGS) segment is expected to grow at the fastest CAGR through the forecast period, driven by decreasing sequencing costs, enhanced analytical capabilities, and growing demand for comprehensive genomic profiling. Online Platforms Dominate Distribution Channel The Online Platforms segment is expected to hold the largest share of the European DTC genetic testing market in 2025, due to the direct-to-consumer nature of these tests and increasing e-commerce adoption. However, the Health Clinics & Laboratories segment is expected to experience the fastest growth rate during the forecast period, driven by increasing integration of genetic testing into routine healthcare and growing physician awareness of genetic testing benefits. Request a customized research analysis tailored to your specific requirements: Regional Market Analysis Netherlands and Nordic Countries to Exhibit the Highest Growth The Netherlands and Nordic countries (Sweden, Denmark, Norway) are witnessing rapid growth rates during the forecast period, primarily driven by progressive healthcare policies, high digital literacy, growing focus on preventive healthcare, and strong government support for genomic medicine initiatives. These regions benefit from advanced healthcare infrastructure and favorable regulatory environments for genetic testing innovation. Germany is expected to hold the largest share of the European DTC genetic testing market in 2025, driven by advanced healthcare infrastructure, high consumer awareness about genetic testing, and significant investments in personalized medicine research, while the U.K. follows as the second-largest market, bolstered by established genetic research institutions and high adoption of digital health technologies. For more comprehensive insights, download the FREE report sample: Market Challenges and Opportunities The European DTC genetic testing market faces challenges including stringent regulatory requirements under GDPR and medical device regulations, concerns about data privacy and genetic discrimination, limited clinical utility of some genetic tests, and varying regulatory frameworks across European countries. Additionally, reimbursement limitations for DTC genetic testing, ethical concerns regarding incidental findings, and the need for genetic counseling services present significant obstacles. Despite these constraints, the market offers substantial growth opportunities through development of pharmacogenetic testing for personalized medication selection, expanding partnerships with healthcare providers, and integration into routine medical care. The growing focus on preventive healthcare and wellness optimization creates new avenues for comprehensive genetic testing solutions. Competitive Landscape The European direct-to-consumer genetic testing market features a diverse competitive landscape with established genetic testing companies, biotechnology specialists, digital health solution providers, and innovative genomics startups pursuing varied approaches to consumer genetic testing implementation. The key players operating in the European DTC genetic testing market include 23andMe, Inc., LLC, MyHeritage Ltd., Living DNA Ltd., Dante Labs S.r.l., tellmeGen S.L., Prenetics Global Limited, Chronomics Limited, GenePlanet d.o.o., ADNTRO Genetics S.L., LetsGetChecked Ltd., Veritas Genetics, Inc., and several other regional and emerging players focusing on specialized genetic testing applications. Leading providers are focusing on comprehensive testing panels that combine multiple genetic insights with personalized health recommendations while addressing region-specific regulatory requirements and privacy concerns. These companies are forming strategic partnerships with healthcare providers, digital health platforms, and research institutions to create integrated genetic testing ecosystems. Recent Industry Developments Companies across the European DTC genetic testing sector continue to invest heavily in technological advancement, regulatory compliance, and expansion into new therapeutic areas. Major players are focusing on developing AI-powered interpretation tools, enhancing data privacy protections, and creating specialized testing panels for specific population groups and health conditions. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More)- Related Industry Reports: Europe DTC Laboratory Testing Market by Application (Genetic Testing {Ancestry, Carrier Status, Disease Risk [Cancer, Neurological, Cardiac]}, Diabetes, Thyroid, STD, Routine, CBC), Sample Type (Saliva, Urine, Blood) - Forecast to 2032 Europe Point-of-Care Diagnostics Market by Application (Influenza, Pneumonia, TB, HAI, Salmonellosis, Hepatitis, HIV, COVID, Pregnancy, Glucose Monitoring, Hematology, Tumor Marker, Urinalysis) Platform (LFA, Molecular) Sample, and End User - Forecast to 2032 Europe Molecular Diagnostics Market by Product (Reagents & Kits, Systems, Software), Test Type (Lab, PoC), Technology (PCR, INAAT, Sequencing, Microarray), Application (Infectious Diseases, Oncology), End User (Hospital, Diagnostic Lab) - Forecast to 2032 About Meticulous Research® Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence, strategic insights, and consulting services to serve clients across 11 major industries globally. The company serves various clients across academics and business leaders from startups to Fortune 500 companies. Meticulous Research® offers comprehensive market research reports, custom research, and consulting services. Our research studies help clients make informed business decisions and understand emerging business trends and opportunities. The company's expertise spans across various domains, enabling it to provide accurate insights and strategic recommendations to its clients. Meticulous Research® is committed to providing accurate and granular research reports to the global business community. To find out more, visit or follow us on LinkedIn Contact:Meticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, U.S. USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content to download multimedia: SOURCE Meticulous Market Research Pvt. Ltd.
Yahoo
an hour ago
- Yahoo
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Verve's lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to cholesterol levels and cardiovascular health. The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD). VERVE-102 is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration. "VERVE-102 has the potential to be the first in vivo gene editing therapy for broad patient populations and could shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment," said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space." "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. "In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly. Lilly shares our vision, and we believe their global research, clinical, regulatory and commercial capabilities will help to accelerate the development of our medicines. My deepest thanks to the entire Verve team for their expertise, creativity, and grit. We are grateful to the investigators and patients who have contributed to the success of our clinical trials so far. Under Lilly's stewardship, we are excited to realize the next chapter in cardiovascular care where a single treatment can lead to lifelong reduction of cardiovascular risk factors and make life better for millions of patients living with cardiovascular disease." Under the terms of the agreement, Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. There can be no assurance that any payments will be made with respect to the CVR. The transaction is not subject to any financing condition and is expected to close in the third quarter of 2025, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Verve's common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of Verve that are not tendered in the tender offer through a second step merger at the same consideration as paid in the tender offer. The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve's common stock ended on June 16, 2025, the last trading day before the announcement of the transaction. Verve's board of directors unanimously recommends that Verve's stockholders tender their shares in the tender offer. To demonstrate their commitment to the transaction, Sekar Kathiresan, Andrew Ashe and entities affiliated with GV have signed tender and support agreements whereby they agreed, subject to certain terms and conditions, to tender their shares in the tender offer. The shares subject to the agreements that are beneficially owned by such stockholders represent a total of approximately 17.8% of Verve's outstanding common stock. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. For Lilly, Kirkland & Ellis LLP is acting as legal counsel. For Verve, Centerview Partners LLC and Guggenheim Securities, LLC are acting as financial advisors and Paul, Weiss, Rifkind, Wharton & Garrison LLP, is acting as legal counsel. About Verve TherapeuticsVerve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's proposed acquisition of Verve, regarding prospective benefits of the proposed acquisition and Verve's gene editing programs for cardiovascular disease, regarding potential contingent consideration amounts and terms, regarding the anticipated occurrence, manner and timing of the proposed tender offer and the closing of the proposed acquisition, regarding Verve's product candidates and ongoing clinical and preclinical development, regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines, and regarding the accounting treatment of the potential acquisition under GAAP and its potential impact on Lilly's financial results and financial guidance. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to consummating the proposed acquisition and any competing offers or acquisition proposals for Verve, drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the potential acquisition and its potential impact on its financial results and financial guidance, uncertainties as to how many of Verve's stockholders will tender their stock in the tender offer, the effects of the proposed acquisition (or the announcement thereof) on Verve's stock price, relationships with key third parties or governmental entities, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, transaction costs, risks that the proposed acquisition disrupts current plans and operations or adversely affects employee retention, potentially diverting management's attention from Verve's ongoing business operations, changes in Verve's business during the period between announcement and closing of the proposed acquisition, and any legal proceedings that may be instituted related to the proposed acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that the proposed acquisition will be completed in the anticipated timeframe or at all, that the conditions required to complete the proposed acquisition will be met, that any event, change or other circumstance that could give rise to the termination of the Merger Agreement will not occur, that Lilly will realize the expected benefits of the proposed acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the proposed acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's and Verve's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, neither Lilly nor Verve undertakes any duty to update forward-looking statements to reflect events after the date of this filing. Additional Information about the Acquisition and Where to Find ItThe tender offer for all of the outstanding shares of Verve described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. A solicitation and offer to buy outstanding shares of Verve will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and Verve will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF VERVE ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF VERVE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of Verve at no expense to them at Lilly's website at and (once they become available) will be mailed to the stockholders of Verve free of charge. The information contained in, or that can be accessed through, Lilly's website is not a part of, or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC's website at In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Verve file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly and Verve with the SEC for free on the SEC's website at Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)Ashlea Kosikowski; ashlea@ (Verve) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Health & Wellness Spa Market Report 2025-2030: Rising Interest in Traditional Treatments and Personalized Packages, & Increased Focus on Teen Wellness Fueling Growth
The global health & wellness spa market, valued at USD 124.23 billion in 2024, is projected to grow to USD 173.74 billion by 2030, at a 5.75% CAGR. Key growth drivers include increasing interest in traditional treatments and personalized packages. Europe leads with a 33% market share. Major players: Marriott, Hilton, and Hyatt. Health & Wellness Spa Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Health & Wellness Spa Market - Focused Insights 2025-2030" report has been added to Health & Wellness Spa Market was valued at USD 124.23 Billion in 2024, and is projected to reach USD 173.74 Billion by 2030, rising at a CAGR of 5.75% The global health & wellness spa market report consists of exclusive data on 38 vendors. The market is highly competitive with many local and international players in the market. Day spas focus on offering a wide range of treatments on a day-use basis. The regional and local operators of health & wellness spas are competing on the quality of treatments, service offerings, and overall customer experience. The companies are focusing on offering personalized services to boost the consumer experience. Luxury hotels and resorts are integrating spa services into their hospitality services offering as a major service and focusing on attracting a wide range of customers. Destination spas are focusing on offering immersive experiences. Medical spas are focusing on offering a wide range of spa services with cosmetic and medical therapies. The companies are focusing on utilizing software-based management for transactions & appointments, utilizing online booking systems, and adopting advanced technology-based treatments that can enhance customer satisfaction and efficiency. Europe dominates and holds the largest global health and wellness spa market share of over 33%. The market is growing significantly due to several factors, including stronger wellness tourism, higher awareness of health and wellness, increased focus on preventive healthcare, rising disposable incomes, an aging population, corporate wellness programs, and concerns related to anti-aging and beauty. In European countries, higher disposable incomes allow people to spend more on a high standard of living, including leisure activities, which drives demand for wellness retreats and spa visits. The rising desire for anti-aging solutions and personal grooming further fuels demand for various spa treatments, including massages, body treatments, skin therapies, and salon services. Additionally, social media platforms are increasingly showcasing the benefits of health and wellness spa experiences, boosting interest across the region. Spa services are expanding significantly in European markets, supported by the strong growth of the tourism sector. With more people choosing Europe as a destination for wellness tourism, the demand for health and wellness spas is expected to grow steadily during the forecast the North American health & wellness spa market is dynamic yet rising significantly and is driven by the desire to maintain health & overall well-being. People are spending more on health-related treatments and services. Moreover, in the region, the U.S. health & wellness spa market is expected to continue to expand, supported by increasing health awareness, rising tourism sector, increasing urbanization, busy lifestyles, increased need for stress reduction, and high disposable incomes. There are over 25,000 spa establishments present in the U.S. HEALTH & WELLNESS SPA MARKET TRENDS & DRIVERS Rising Interest in Traditional Treatments and Personalized PackagesThe demand for traditional treatments is growing significantly due to several factors, including authenticity, perceived effectiveness, cultural exploration, and a holistic approach. The demand for personalized packages is growing significantly due to several factors, including increased health awareness, changing consumer preferences, and the desire for results. The traditional practices are known for their holistic approaches toward wellness. It addresses the body, spirit, and mind. Many people believe that traditional therapies are known for their efficacy. People are continuously traveling which explore various cultures, which gives more information about the traditional healing methods. It leads to driving the demand for the wellness spa market. The personalized wellness programs include integrating customized nutrition plans, fitness regimens, and mental health therapies to promote holistic well-being and long-term health benefits. Programs may include yoga, pilates, strength training, cardio exercises, and outdoor activities based on client preferences and wellness Focus on Teen WellnessThe increased focus on teen wellness is a major and noticeable trend. It is driven by several factors, including increased focus on resolving mental health issues in teenagers, early intervention, unique stressors, increased awareness about the health & wellness of teens, and changing perception about wellness spas. The wellness industry players have started targeting this demographic more seriously. The wellness industry is growing with the targeting of teenagers by offering a wider variety of programs and services. The rising awareness among educators and parents about the importance of teen wellness drives the demand for the wellness apps market. The Hyatt Corporation is offering wellness programs for families. The rising recognition of the mental health concerns faced by teenagers, such as stress, anxiety, and depression, increases the need for wellness services and programs. Teenagers are facing unique stressors due to social pressure, academics, and body of Stressful LifestyleThe prevalence of stressful lifestyles is a significant driver in the global wellness spa market. It is driven by several factors, including mental health concerns, digital overload, increased awareness of stress impact, fast-paced urban environments, rising work pressures, and desire for self-care. The rising rates of depression, anxiety, and many other health conditions have increased the need for stress reduction programs and therapies. The global mental wellness market is rising significantly as work-related stress, anxiety, and depression are becoming more prevalent. The spa services companies are focusing on offering various new treatments for the reduction of stress, such as meditation sessions, sleep therapy, and mindfulness Focus on Health & WellnessThe rising focus on health & wellness is a major driver in the global wellness spa market. It is driven by several factors, including rising consumer awareness, changing consumer needs, busy lifestyles, and rising spending on health & wellness. Consumers are prioritizing self-care activities and seeking a better work-life balance, which can contribute to overall wellness. The fast-paced lifestyles, with their digital overload and work pressures, have increased stress levels. People are seeking new ways to overcome these challenges. The businesses are continuously recognizing the importance of the well-being of employees and focusing on offering wellness therapies & programs for reducing healthcare costs and improving RESTRAINTS Lack of Skilled WorkforceThe lack of a skilled workforce is a significant challenge in the health & wellness spa market due to several factors. It includes high turnover rates, growing demand, specialized skills, and varying training standards. The spa industry is experiencing high employee turnover because of various factors such as demanding physical strain, work schedules, and lower pay in some regions. The rapid growth of the health & wellness industry is facing a shortage of the number of certified professionals. Certification and training standards for spa professionals may change as per the regions and countries. It can lower the quality of services and outpace the professionals with the required expertise. NEW PRODUCT DEVELOPMENTS In 2024, Marriott International, Inc. launched one of its beachfront destination hotels, Khao Lak Marriott Beach Resort & Spa, in Thailand. Marriott Bonvoy's hotels in Khao Lak offer a serene and authentic experience, blending modern comforts with traditional Thai hospitality. The Spa menus of the hotel feature body scrubs and wraps, facials, foot baths, manicures, pedicures, steam rooms, and therapy baths. It provides a special range of award-winning signature massage treatments, all designed to revitalize the consumers. In 2024, Hilton launched its first flagship property, Hilton Gurugram Baani City Centre in Delhi, India. It's a 223-room hotel facility offering state-of-the-art facilities along with wellness and spa centers. KEY TAKEAWAYS By Service: The massage and body treatments segment holds the largest market share of over 56%, driven by the effectiveness of massages in reducing anxiety, stress, and depression. By Facility: The destination spas show the highest growth of 6.30%, driven by comprehensive wellness packages and their tranquil, scenic locations. By Gender: The women gender accounted for the largest market share, the growth is driven by the rising wellness trends, increased awareness of health & wellness, and skin health & anti-aging concerns. By End-User: The teenagers and children segment shows the highest growth, driven by rising parental awareness of the long-term benefits of spa treatments. By Geography: Europe dominates and holds the largest health & wellness spa market share of over 33%, driven by the increased emphasis on relaxation, preventive health, and well-being, fueling the wellness economy in the European markets. Growth Factor: The global health & wellness spa market is set to grow due to the prevalence of stressful lifestyles and rising interest in traditional treatments and personalized packages. KEY QUESTIONS ANSWERED How big is the global health & wellness spa market? Which region holds the largest share in the global health & wellness spa market? Which service segment has the largest share in the global health & wellness spa market? Which facility segment provides more business opportunities in the global health & wellness spa market? Who are the major players in the global health & wellness spa market? Key Attributes: Report Attribute Details No. of Pages 139 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $124.23 Billion Forecasted Market Value (USD) by 2030 $173.74 Billion Compound Annual Growth Rate 5.7% Regions Covered Global Key Vendors Accor S.A. Four Seasons Hotels Limited Hilton Hyatt Corporation IHG Hotels & Resorts Marriott International, Inc. Other Prominent Vendors OneSpaWorld Holdings Limited Massage Envy Hand & Stone Franchise Corp. Mandarin Oriental Hotel Group Limited Oetker Hotel Management Company GmbH Kempinski Hotels Siam Wellness Group Lanserhof Aman Group S.a.r.l. Chiva-Som Blue Lagoon Terme di Saturnia Therme Group Vy Resort Thermal & Spa AYANA Hospitality Baden-Baden Kur & Tourismus GmbH Caldea Canyon Ranch Elementia Wellness Pvt. Ltd. Elemis Gellert Merit International Hotels & Resorts Minor International PCL Onsen Hot Pools Queenstown Ltd Papallacta Hot Springs Peninsula Hot Springs Pty Ltd Planet Beach Franchising Corporation Rancho La Puerta Inc. Rescue Spa Tabacon Thermal Resort & Spa Termas de Puyehue Hotel Woodhouse Spa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Health & Wellness Spa Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
